Drugs / ZP9830
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06682975 | Nov 2024 → Aug 2026 overdue | — | Zealand Pharma | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-18 | Zealand Pharma | Results Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 zealandpharma.com ↗
Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced positive Phase 1a single ascending dose (SAD) topline results for the company’s Kv1.3 channel blocker, ZP9830. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-02-18 | Zealand Pharma | Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 zealandpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZP9830 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06682975 ↗ |
| Route | Subcutaneous | “given subcutaneously (s.c., under the skin)” NCT06682975 ↗ |